Cingulate

Cingulate Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Cingulate (CING) as of Oct 22, 2026 is -1,373.70. In the previous year, Cash Conversion Cycle (CCC) was -740.60 — a change of 85.48% (lower).

Cash Conversion Cycle

-1,373.70

YoY

85.48%

Last updated:

Cash Conversion Cycle (CCC) of Cingulate is 2025 -1,373.70 . Cash Conversion Cycle (CCC) of Cingulate was 2024 -740.60 . It decreases by 85.48% lower compared to the previous year.

The Cingulate Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2019
-3,867.81 USD
Jan 1, 2020
-422.53 USD
Jan 1, 2021
-430.72 USD
Jan 1, 2022
-388.49 USD
Jan 1, 2023
-3,264.63 USD
Jan 1, 2024
-740.60 USD
Jan 1, 2025
-1,373.70 USD
The Cingulate Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-1,373.70+85.48%
-740.60-77.31%
-3,264.63+740.34%
-388.49-9.80%
-430.72+1.94%
-422.53-89.08%
-3,867.81—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Cash Conversion Cycle (CCC) of Cingulate is -1,373.70 in 2025.

Cash Conversion Cycle (CCC) of Cingulate changed from -740.60 to -1,373.70, representing a 85.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Cingulate since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Cingulate with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Cingulate

All Key Metrics — Cingulate